Advertisement

Hereditärer Brust- und Eierstockkrebs

  • Teresa Wagner
  • Gudrun Langbauer
  • Regina Möslinger
  • Martin Schreiber
  • Elisabeth Fleischmann
  • Ernst Kubista
  • Daniela Muhr
  • Michaela Hareter
  • Ingeborg Lachner
  • Petra Kofler
Part of the Molekulare Medizin book series (MOLMED)

Zusammenfassung

Brustkrebs ist in den meisten industrialisierten Ländern das häufigste Karzinom der Frau. Weltweit werden pro Jahr etwa 1 Mio. Frauen mit Brustkrebs diagnostiziert (Kelsey u. Horn-Ross 1993). Das Risiko für Frauen, im Lauf ihres Lebens an Brustkrebs zu erkranken, beträgt etwa 10–12%. Etwa 50% der Brustkrebsfälle treten nach dem 60. Lebensjahr auf und sind durch das Lebensalter bzw. verschiedenste Risikofaktoren bedingt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Andersen TI, Borresen A-L, Moller PA (1996) Common BRCA1 mutation in Norwegian breast and ovarian cancer families? Am J Hum Genet 59:486–487PubMedGoogle Scholar
  2. Antoniou AC, Gayther SA, Stratton JF et al. (2000) Risk models for familial ovarian and breast cancer. Genet Epidemiol 18:173–190PubMedCrossRefGoogle Scholar
  3. Banin S, Moyal, L Shieh S et al. (1998) Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281:1674–1677PubMedCrossRefGoogle Scholar
  4. Bell DW, Varley JM, Szydlo TE et al. (1999) Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286:2528–2531PubMedCrossRefGoogle Scholar
  5. Bennett IC, Gattas M, Teh BT (1999) The genetic basis of breast cancer and its clinical implications. Aust N Z J Surg 69:95–105PubMedCrossRefGoogle Scholar
  6. Bertwistle D, Ashworth A (1998) Functions of the BRCA1 and BRCA2 genes. Curr Opin Genet Dev 8:14–20PubMedCrossRefGoogle Scholar
  7. Bewtra C, Watson P, Conway T et al. (1992) Hereditary ovarian cancer: a clinicopathological study. Int J Gynecol Pathol 11:180–187PubMedCrossRefGoogle Scholar
  8. Boyd J, Rubin SC (1997) Hereditary ovarian cancer: molecular genetics and clinical implications. Gynecol Oncol 64:196–206PubMedCrossRefGoogle Scholar
  9. Boyd J, Sonoda Y, Federici MG et al. (2000) Clinicopathological features of BRCA-linked and sporadic ovarian cancer. JAMA 283:2260–2265PubMedCrossRefGoogle Scholar
  10. Breast Cancer Linkage Consortium (1997) Pathology of familial breast cancer: differences between breast cancer in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349:1505–1510CrossRefGoogle Scholar
  11. Broca P (1866) Traite de tumeurs. Asselin, ParisGoogle Scholar
  12. Bronner CE, Baker SM, Morrison PT et al. (1994) Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 368:258–261PubMedCrossRefGoogle Scholar
  13. Buckbinder L, Talbott R, Velasco Miguel S et al. (1995) Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377:646–649PubMedCrossRefGoogle Scholar
  14. Callebaut I, Mornon JP (1997) From BRCA1 to RAPI: a widespread BRCT module closely associated with DNA repair. FEBS Lett 400:25–30PubMedCrossRefGoogle Scholar
  15. Caman CE, Lin DS, Cimprich Ka et al. (1998) Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281:1677–1679CrossRefGoogle Scholar
  16. Chappuis PO, Rosenblatt J, Foulkes WD (1999) The influence of familial and hereditary factors on the prognosis. Ann Oncol 10:1163–1170PubMedCrossRefGoogle Scholar
  17. Cortez D, Wang Y, Qin J et al. (1999) Requirement of ATM-dependent phosphorylation of brcal in the DNA damage response to double-strand breaks. Science 286:1162–1166PubMedCrossRefGoogle Scholar
  18. Couch FJ, Weber BL (1998) Breast cancer. In: Vogelstein B, Kinzler KW (eds) The genetic basis of human cancer. McGraw-Hill, New York, pp 537–564Google Scholar
  19. Couch FJ, DeShano ML, Blackwood A et al. (1997) BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336:1409–1415PubMedCrossRefGoogle Scholar
  20. Croyle RT, Achilles JS, Lerman C (1997) Psychologic aspects of cancer genetic testing. Cancer 80:569–575PubMedCrossRefGoogle Scholar
  21. Dahia PL, Aguiar RC, Alberta J et al. (1999) PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in haematological malignancies. Hum Mol Genet 8:185–193PubMedCrossRefGoogle Scholar
  22. Darwin C (1871/deutsch1982) Die Abstammung des Menschen.Aus dem Englisschen übersetzt von H. Schmidt. Schweizerbarr, StuttgartGoogle Scholar
  23. Fishel R, Ewel A, Lee S et al. (1994) Binding of mismatched microsatellite DNA sequences by the human MSH2 protein. Science 266:1403–1405PubMedCrossRefGoogle Scholar
  24. Fisher B, Costantino JP, Wickerham DL et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388PubMedCrossRefGoogle Scholar
  25. Ford D, Easton DF, Bishop DT et al. (1994) Risks of cancer in BRCA1-mutation carriers. Lancet 343:692–695PubMedCrossRefGoogle Scholar
  26. Ford D, Easton DF, Petro J (1995) Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57:1457–1462PubMedGoogle Scholar
  27. Ford D, Easton DF, Stratton M et al. (1998) Genetic heterogeneity and penetranceanalysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62:676–689PubMedCrossRefGoogle Scholar
  28. Foulkes WD, Chppuis PO, Wong N et al. (2000) Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Ann Oncol 11:307–313PubMedCrossRefGoogle Scholar
  29. Friedman E, Bruchim RB-S, Kruglikova A et al. (1998) Double heterozygotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genes. Am J Hum Genet 63:1224–1227PubMedCrossRefGoogle Scholar
  30. Galton F (1865) Hereditary talent and character. Macmillans Magazine 12:157–166,318-327Google Scholar
  31. Galton F (1905) Eugenics. Its definition, scope, and aims. Sociological Papers 1:45–50Google Scholar
  32. Gatti RA (1998) Ataxia-telangiectasia. In: Vogelstein B, Kinzler KW (eds) The genetic basis of human cancer. McGraw-Hill, New York, pp 275–300Google Scholar
  33. Gatti RA, Concannon P (2000) Cancer susceptibility in ATM heterozygotes: do two distinct populations exist? Breast Cancer Res 2:S13CrossRefGoogle Scholar
  34. Gayther SA, Harrington P, Russell P et al. (1997) Frequently occurring germ-line mutations of the BRCA1 gene in ovarian cancer families from russia. Am J Hum Genet 60:1239–1242PubMedGoogle Scholar
  35. Gayther SA, Mangion J, Russell P et al. (1997) Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 15:103–105PubMedCrossRefGoogle Scholar
  36. Grann VR, Jacobson JS, Whang W et al. (2000) Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis. Cancer J 6:13–20Google Scholar
  37. Hagmann M (1999) Checkpoint gene linked to human cancer. Science 286:2433–2434PubMedCrossRefGoogle Scholar
  38. Hakansson S, Johannsson O, Johansson U et al. (1997) Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer. Am J Hum Genet 60:1068–1078PubMedGoogle Scholar
  39. Hakem R, Pompa JL de la, Elia A et al. (1997) Partial rescue of Brca1 (5–6) early embryonic lethality by p53 or p21 null mutation. Nat Genet 16:298–302PubMedCrossRefGoogle Scholar
  40. Hall JM, Lee MK, Newman B et al. (1990) Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250:1684–1689PubMedCrossRefGoogle Scholar
  41. Harris CC, Hollstein M (1993) Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329:1318–1327PubMedCrossRefGoogle Scholar
  42. Hartmann LC, Schaid DJ, Woods JE et al. (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340:77–84PubMedCrossRefGoogle Scholar
  43. Hopper JL, Southey MC, Dite GS et al. (1999) Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncation mutations in BRCA1 and BRCA2. Cancer Epidemiol 8:741–747Google Scholar
  44. Jacks T, Weinberg RA (1996) Cell-cycle control and its watchman. Nature 381:643–644PubMedCrossRefGoogle Scholar
  45. Kelsey JL, Horn-Ross PL (1993) Breast cancer: magnitude of the problem and descriptive epidemiology. Epidemiol Rev 15:7–16PubMedGoogle Scholar
  46. Kinzler KW, Vogelstein B (1997) Gatekeepers and caretakers. Nature 386:761–763PubMedCrossRefGoogle Scholar
  47. Knudson AG (1971) Mutation and cancer statistical Studie of retinoblastoma. Proc Natl Acad Sci USA 68:820–823PubMedCrossRefGoogle Scholar
  48. Lakhani SR, Jacquemier J, Sloane JP et al. (1998) Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90:1138–1145PubMedCrossRefGoogle Scholar
  49. Leach FS, Nicolaides NC, Papadopoulos N et al. (1993) Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75:1215–1225PubMedCrossRefGoogle Scholar
  50. Lee JS, Wacholder S, Struewing JP et al. (1999) Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 91:259–263PubMedCrossRefGoogle Scholar
  51. Lerman C, Narod S, Schulman K et al. (1996) BRCA1 testing in families with hereditary breast-ovarian cancer. JAMA 275:1885–1892PubMedCrossRefGoogle Scholar
  52. Lerman C, Schwartz MD, Lin TH et al. (1997) The influence of psychological distress on use of genetic testing for cancer risk. J Consul Clin Psychol 65:414–420CrossRefGoogle Scholar
  53. Lerman C, Hughes C, Lemon SJ et al. (1998) What you don't know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing. J Clin Oncol 16:1650–1654PubMedGoogle Scholar
  54. Levine AJ (1997) p53: the cellular gatekeeper for growth and division. Cell 88:323–331PubMedCrossRefGoogle Scholar
  55. Li J, Yen C, Liaw D et al. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943–1947PubMedCrossRefGoogle Scholar
  56. Li J, Simpson L, Takahashi M et al. (1998) The PTEN/ MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. Cancer Res 58:5667–5672PubMedGoogle Scholar
  57. Liaw D, Marsh DJ, Li J et al. (1997) Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16:64–67PubMedCrossRefGoogle Scholar
  58. Ludwig T, Chapman DL, Papaioannou VE et al. (1997) Targeted mutations of breastcancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev 11:1226–1241PubMedCrossRefGoogle Scholar
  59. Lynch HT, Guirgis HA, Brodkey F et al. (1976) Genetic heterogeneity and familial carcinoma of the breast. Surg Gynecol Obstet 142:693–699PubMedGoogle Scholar
  60. Lynch HT, Lemon S, Durham C et al. (1997) A descriptive study of BRCA1 testing and reactions to disclosure of test results. Cancer 79:2219–2228PubMedCrossRefGoogle Scholar
  61. Maehama T, Dixon JE (1998) The tumor suppressor, PTEN/ MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273:13.375–13.378CrossRefGoogle Scholar
  62. Malkin D (1998) Li-Fraumeni syndrome. In: Vogelstein B, Kinzler KW (eds) The genetic basis of human cancer. McGraw-Hill, New York, pp 393–408Google Scholar
  63. Malone KE, Daling JR, Thompson JD et al. (1998) BRCA1 mutations and breast cancer in the general population. JAMA 279:922–929PubMedCrossRefGoogle Scholar
  64. Marsh DJ, Coulon V, Lunetta KL et al. (1998a) Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 7:507–515PubMedCrossRefGoogle Scholar
  65. Marsh DJ, Dahia PL, Caron S et al. (1998b) Germline PTEN mutations in Cowden syndrome-like families. J Med Genet 35:881–885PubMedCrossRefGoogle Scholar
  66. Meijers-Heijboer EJ, Geel AN van, Seynaeve C et al. (1997) Uptake presymptomatic DNA test and preventive measures in families with inherited breast-and/or ovarian cancer. Am J Hum Genet [Suppl] 61:A74Google Scholar
  67. Miki Y, Swensen J, Shattuck-Eidens D et al. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71PubMedCrossRefGoogle Scholar
  68. Miller BA (1993) SEER cancer statistics review: 1973-90 NIH Publication 1993:2789–2793Google Scholar
  69. Miyashita T, Krajewski S, Krajewska M et al. (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799–1805PubMedGoogle Scholar
  70. Myers MP, Pass I, Batty IH et al. (1998) The lipid phosphatase activity of PTEN is critical for its tumor suppressor function. Proc Natl Acad Sci USA 95:13.513–13.518CrossRefGoogle Scholar
  71. Narod SA, Risch H, Moslehi R et al. (1998) Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 339:424–428PubMedCrossRefGoogle Scholar
  72. Neuhausen SL, Mazoyer S, Friedman L et al. (1996) Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. Am J Hum Genet 58:271–280PubMedGoogle Scholar
  73. Newman B, Austin MA, Lee M et al. (1988) Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families. Proc Natl Acad Sci USA 85:3044–3048PubMedCrossRefGoogle Scholar
  74. Nicolaides NC, Papadopoulos RD, Liu B et al. (1994) Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 371:75–80PubMedCrossRefGoogle Scholar
  75. Oddoux C, Struewing JP, Clayton CM et al. (1996) The carrier frequency of the BRCA2 617delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 14:188–190PubMedCrossRefGoogle Scholar
  76. Papadopoulos N, Nicolaides NC, Wei YF et al. (1994) Mutation of a mutL homolog in hereditary colon cancer. Science 263:1625–1629PubMedCrossRefGoogle Scholar
  77. Papp J, Raicevic L, Milasin J et al. (1999) Germline mutation analysis of BRCA1 and BRCA2 genes in Yugoslav breast/ ovarian cancer families. Oncol Rep 6:1435–1438PubMedGoogle Scholar
  78. Peto J, Collins N, Barfoot R et al. (1999) Prevalence of BRCA1and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91:943–949PubMedCrossRefGoogle Scholar
  79. Petrij-Bosch A, Peelen T, Vliet M van et al. (1997) BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet 17:341–345PubMedCrossRefGoogle Scholar
  80. Pharaoh PDP, Easton DF, Stockton DL et al. (1999) Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. Cancer Res 59:868–871Google Scholar
  81. Powles T, Eeles R, Ashley S et al. (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352:98–101PubMedGoogle Scholar
  82. Rebbeck TR, Levin AM, Eisen A et al. (1999) Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91:1475–1479PubMedCrossRefGoogle Scholar
  83. Reed SC (1974) A short history of genetic counselling. Soc Biol 24:332–339Google Scholar
  84. Roa BB, Boyd A A, Volcik K et al. (1996) Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14:185–187PubMedCrossRefGoogle Scholar
  85. Robson M, Levin D, Federici M et al. (1999) Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst 91:2112–2117PubMedCrossRefGoogle Scholar
  86. Rotman G, Shiloh Y (1999) ATM: a mediator of multiple responses to genotoxic stress. Oncogene 18:6135–6144PubMedCrossRefGoogle Scholar
  87. Rubin SC, Benjamin I, Behbakht K et al. (1996) Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 335:1413–1416PubMedCrossRefGoogle Scholar
  88. Schräg D, Kuntz KM, Garber JE et al. (2000) Life expectancy hains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA 283:617–624PubMedCrossRefGoogle Scholar
  89. Schultz LB, Weber BL (1999) Recent advances in breast cancer biology. Curr Opin Oncol 11:429–434PubMedCrossRefGoogle Scholar
  90. Society AC (1996) Cancer facts and figures. Society AC AtlantaGoogle Scholar
  91. Stambolic V, Suzuki A, Pompa JL de la et al. (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95:29–39PubMedCrossRefGoogle Scholar
  92. Steck PA, Pershouse MA, Jasser SA et al. (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15:356–362PubMedCrossRefGoogle Scholar
  93. Struewing JP, Abeliovich D, Peretz T et al. (1995) The carrier frequency of the BRCA1 185delAG mutation is approcimately 1 percent in Ashkenazi Jewish individuals. Nat Genet 11:198–200PubMedCrossRefGoogle Scholar
  94. Struewing JP, Hartge P, Wacholder S et al. (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401–1408PubMedCrossRefGoogle Scholar
  95. Tavtigian SV, Simard J, Rommens J et al. (1996) The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 12:333–337PubMedCrossRefGoogle Scholar
  96. Thorlacius S, Sigurdsson S, Bjarnadottir H et al. (1997) Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet 60:1079–1084PubMedGoogle Scholar
  97. Thorlacius S, Struewing JP, Hartge P et al. (1998) Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 352:1337–1339PubMedCrossRefGoogle Scholar
  98. Venkitaraman AR(1999) Breast cancer genes and DNA repair. Science 286:1100–1102PubMedCrossRefGoogle Scholar
  99. Verhoog LC, Brekelmans CTM, Seynaeve C et al. (1998) Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 351:316–321PubMedCrossRefGoogle Scholar
  100. Veronesi U, Maisonneuve P, Costa A et al. (1998) Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italiantamoxifen preventionstudy. Lancet 1998:352Google Scholar
  101. Wagner TMU, Möslinger RA, Muhr D et al. (1998) BRCA1-related breast cancer in Austrian breast and ovarian cancer families: specific BRCA1 mutations and pathological characteristics. Int J Cancer 77:354–360PubMedCrossRefGoogle Scholar
  102. Wagner T, Möslinger R, Langbauer G et al. (2000) Attitude towards prophylactic surgery and effects of genetic counselling in families with BRCA mutations. Br J Cancer 82:1249–1253PubMedCrossRefGoogle Scholar
  103. Warner E, Foulkes W, Goodwin P et al. (1999) Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 91:1241–1247PubMedCrossRefGoogle Scholar
  104. Welcsh PL, Owens KN, King M-C (2000) Insights into the functions of BRCA1 and BRCA2. Trends Genet 16:69–74PubMedCrossRefGoogle Scholar
  105. Wooster R, Neuhausen SL, Mangion J et al. (1994) Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13ql2-13. Science 265:2088–2090PubMedCrossRefGoogle Scholar
  106. Wooster R, Bigneil G, Lancaster J et al. (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789–792PubMedCrossRefGoogle Scholar
  107. Zhang H, Tombline G, Weber BL (1998) BRCA1, BRCA2, and DNA damage response: collision or collusion? Cell 92:433–436PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • Teresa Wagner
    • 1
  • Gudrun Langbauer
    • 1
  • Regina Möslinger
    • 1
  • Martin Schreiber
    • 1
  • Elisabeth Fleischmann
    • 1
  • Ernst Kubista
    • 1
  • Daniela Muhr
  • Michaela Hareter
  • Ingeborg Lachner
  • Petra Kofler
  1. 1.Abteilung für Spezielle GynäkologieUniversitätsklinik für Frauenheilkunde Allgemeines Krankenhaus der Stadt WienWienÖosterreich

Personalised recommendations